Biogen Finds More PML In The Woodpile (BIIB)
Biogen Idec Inc. (NASDAQ: BIIB has notified regulatory agencies of a confirmed case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with TYSABRI .
Biogen Idec Inc. (NASDAQ: BIIB has notified regulatory agencies of a confirmed case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with TYSABRI .
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is feeling the wrath of the trading gods today. Shares are down some 74% at $2.95 in close to 10-times normal trading volume. The culprit for today’s biotech implosion…
Thoratec Corporation (NASDAQ: THOR) is having a rough morning. The heart failure device company has a product recall it announced last Friday, and medical device recalls are not what the public likes to hear…
Today after the close, SEC Filings have shown that Boston Scientific Corp. (NYSE: BSX) co-founders have been forced to sell more common stock to meet margin calls. Unfortunately this isn’t the first pony ride…
Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted earnings of $1.23 non-GAAP EPS and $3.875 billion in revenues. First Call had estimates…
Dynavax Technologies Corp. (NASDAQ: DVAX) is the latest biotech implosion as shares are down some 75% today. The company gave an update on an FDA clinical hold on its investigational vaccine HEPLISAV with partner…
Once all of the one-time charges were washed out of the numbers, Pfizer recorded adjusted income of $4.2 billion, an increase of 5% compared with $4.0 billion in the year-ago quarter, and EPS of $.62,…
Syneron Medical Ltd. (ELOS) is generally a thin volume stock, although it may see more active trading as the opening bell gets closer. Shares are indicated lower on an earnings warning. It sees $0.11…
Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS and $1.37 billion in revenue. First Call had estimates at $0.49 non-GAAP EPS and…
Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call estimates of $0.88 on $3.36 billion in revenue. For what this is worth, Genentech…
After today’s close, we are expecting the earnings report of of biotech giant Genentech, Inc. (NYSE: DNA). First Call estimates are for $0.88 EPS on $3.36 billion in revenue. Today is going to be…
Johnson & Johnson (NYSE: JNJ) is showing that some companies can get it right despite tough times. The company has beat earnings and is even raising its fiscal 2008 guidance. The consumer products and…
A lot of people believe that Merck (MRK) knew a lot more about the dangers of its arthritis drug Vioxx than the company ever let on. Heart problems were apparently a by-product of using…
If you think things are bad here in the U.S., Iceland is experiencing something far worse. The country is on the verge of teetering, it is nationalizing its banks, and it is on the…
Dendreon Corp. (NASDAQ: DNDN) was an incredible performer today, and one which makes you wonder how well it would have done had the stock market not been so ugly. Its interim data from Phase…